Boryung Pharmaceutical Co., Ltd. and Macrogen Inc. start the genome analysis service in earnest.

The two companies have signed on 20 July a business agreement for the joint entry into the genome analysis service enterprise and the development of the Personalized Genomic Medicine.

And as of 20 July, they also have introduced 'G-scanning' checkup for the first time in Korea as an output of their first joint business.

'G-scanning (genome scanning)' checkup is a new concept of the genome analysis service, using the most advanced life science technology such as DNA chips via which can be scanned a wide range of genomic parts(about 1440) of the human body.

By only once untramodern scanning, 'G-scanning' checkup makes possible to get the individual's private genomic information and to diagnose mental retardation, epilepsy, learning disability, undergrowth and various kinds of rare diseases, that are all caused by genomic abnormalities.

The decoded individual's private genomic information will be kept for 10 years and updated as occasion demands.

In the beginning, the two companies are to offer 'G-scanning' checkup only for the newborn, the infant and the child and to gradually extend the service for the adult in due course.

They are expecting that 'G-scanning' checkup will play the role of locomotive for advancing the era of Personalized Genomic Medicine based on the individual's private genomic information.<헬스코리아뉴스>

▲ 보령제약, 마크로젠과 유전체 분석 사업 공동 진행

Healthkoreanews 다른기사 보기